GSA Capital Partners’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

GSA Capital Partners’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,815	Closed	-$441K	–	1986
2022 Q3	$441K	Sell	20,815 -1,420	-6%	-$38.3K	0.06%	666
2022 Q2	$539K	Buy	22,235 +18,389	+478%	+$626K	0.08%	453
2022 Q1	$192K	Buy	3,846 +179	+5%	+$8.85K	0.03%	1179
2021 Q4	$257K	Buy	+3,667	New	+$309K	0.03%	1043
2021 Q3	–	Sell	-6,259	Closed	-$629K	–	1849
2021 Q2	$629K	Buy	6,259 +2,122	+51%	+$207K	0.07%	490
2021 Q1	$386K	Sell	4,137 -140	-3%	-$14.2K	0.06%	490
2020 Q4	$353K	Buy	4,277 +1,614	+61%	+$138K	0.06%	653
2020 Q3	$228K	Buy	+2,663	New	+$310K	0.04%	924

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GSA Capital Partners's VBIV Position: Q4 2022 in Review

GSA Capital Partners sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2022, closing a stake of 20,815 shares — an estimated $441K sold.

GSA Capital Partners first reported a position in VBIV in Q3 2020 and held it in 8 quarters. The position peaked at $629K in Q2 2021. 111 funds tracked by Wall St. Rank hold VBIV as of Q4 2022.

GSA Capital Partners reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 20,815 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2022, an estimated $441K.
GSA Capital Partners first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2020 and held it in 8 quarters.
GSA Capital Partners's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $629K in Q2 2021.
111 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.